1.75
전일 마감가:
$1.81
열려 있는:
$1.8
하루 거래량:
24,057
Relative Volume:
0.90
시가총액:
$9.62M
수익:
-
순이익/손실:
$-14.29M
주가수익비율:
-0.4386
EPS:
-3.99
순현금흐름:
$-12.27M
1주 성능:
+0.57%
1개월 성능:
+1.16%
6개월 성능:
-50.00%
1년 성능:
-62.79%
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
APRE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
APRE
Aprea Therapeutics Inc
|
1.75 | 9.62M | 0 | -14.29M | -12.27M | -3.99 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2020-12-16 | 개시 | Berenberg | Buy |
2020-09-29 | 재개 | JP Morgan | Neutral |
2020-06-22 | 개시 | H.C. Wainwright | Neutral |
2020-04-21 | 개시 | Robert W. Baird | Outperform |
2019-10-28 | 개시 | JP Morgan | Neutral |
2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MSN
Aprea Therapeutics expands cancer drug patent portfolio - MSN
BNP Paribas Financial Markets Takes $43,000 Position in Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Ovarian Cancer Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Q2 Earnings Estimate for APRE Issued By Wedbush - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Earns “Buy” Rating from B. Riley - Defense World
The Manufacturers Life Insurance Company Sells 752 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) - Defense World
The Manufacturers Life Insurance Company Purchases 993 Shares of CTO Realty Growth, Inc. (NYSE:CTO) - Defense World
InMode Ltd. (NASDAQ:INMD) Shares Sold by The Manufacturers Life Insurance Company - Defense World
What is Wedbush’s Estimate for ORKA FY2029 Earnings? - Defense World
Wedbush Forecasts Lower Earnings for Aprea Therapeutics - Defense World
Petro-Victory Energy Corp. Announces Short Term Loan - Barchart.com
Stocks Close Higher On Optimism Over US Trade Negotiations - Barchart.com
Ontario Lottery And Gaming CorporationMidDay Lottery Winning NumbersMay 16, 2025 - Barchart.com
Becton, Dickinson And Company Stock: Analyst Estimates & Ratings - Barchart.com
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance - Barchart.com
Strathcona Resources Ltd. Reports First Quarter 2025 Financial and Operating Results, Announces Quarterly Dividend and Investment in MEG Energy Corp. - Barchart.com
Aprea Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
NoticeGO-TO DEVELOPMENTS HOLDINGS INC., GO-TO SPADINA ADELAIDE SQUARE INC., FURTADO HOLDINGS INC., and OSCAR FURTADO, File No. 2022-8 - Barchart.com
RBC Global Asset Management Inc. Announces RBC ETF Cash Distributions For May 2025 - Barchart.com
Strathcona Resources Ltd. Announces Sale of Montney Business for $2.84 Billion and Acquisition of Hardisty Rail Terminal - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Barchart.com
Psychemedics Named “Most Innovative Drug Testing Company Of The Year” - Barchart.com
This Under-The-Radar Cancer Biotech Reports 21% Tumor Shrinkage: Analysts See 600%+ Upside - Barchart.com
GFL Environmental Inc. Announces Results From Annual General Meeting Of Shareholders - Barchart.com
Aprea (APRE) Reports Q1 Revenue Drop Amid Clinical Progress | AP - GuruFocus
APRE Reports Decrease in Cash Reserves by End of Q1 2025 | APRE Stock News - GuruFocus
Aprea Therapeutics Reports Promising Q1 2025 Results - TipRanks
Aprea Therapeutics reports Q1 EPS (66c) vs. (67c) last year - TipRanks
Aprea Therapeutics, Inc. SEC 10-Q Report - TradingView
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - The Manila Times
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewswire Inc.
Stocks In Play: Knight Therapeutics Inc - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) To Report Q1 2025 Results On May 15 - Barchart.com
Aprea Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Stocks In Play: Galiano Gold Inc. - Barchart.com
Stocks In Play: Illumin Holdings Inc. - Barchart.com
PBYI Stock Rises As Q1 Earnings And Sales Beat Estimates - Barchart.com
Japanese Tech Company Panasonic Cuts 4% Of Its Global Workforce As Profits Falter - Barchart.com
LifeSpeak Inc. Announces First Quarter 2025 Results - Barchart.com
Stocks In Play: Knight Therapeutics Inc. - Barchart.com
PIZZA PIZZA ROYALTY CORP. ANNOUNCES FIRST QUARTER 2025 RESULTS - Barchart.com
Adicet Bio Advances Two Breakthrough Therapies: Key Clinical Data Coming in 2025 for Lupus and Cancer Programs - Stock Titan
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire
IGM FINANCIAL INC. ANNOUNCES APRIL 2025 ASSETS UNDER MANAGEMENT & ADVISEMENT AND NET FLOWS - Barchart.com
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MyChesCo
LPL Financial LLC Makes New $53,000 Investment in Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
3 Consumer Discretionary Stocks to Buy in a Divided Economy - The Globe and Mail
Carnival Corporation Earnings Preview: What To Expect - Barchart.com
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aprea Therapeutics Inc 주식 (APRE) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Duey Marc | Director |
Oct 18 '24 |
Sale |
4.58 |
6,462 |
29,583 |
233,651 |
Gilad Oren | President/CEO |
Oct 23 '24 |
Buy |
3.92 |
500 |
1,958 |
333,395 |
Duey Marc | Director |
Oct 16 '24 |
Buy |
4.39 |
30,000 |
131,700 |
240,113 |
Gilad Oren | President/CEO |
Oct 15 '24 |
Buy |
2.90 |
250 |
725 |
332,895 |
Duey Marc | Director |
Oct 14 '24 |
Buy |
2.58 |
190 |
490 |
210,113 |
Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 11 '24 |
Buy |
2.46 |
50 |
123 |
19,368 |
Seizinger Bernd R. | Director |
Oct 11 '24 |
Buy |
2.68 |
10,000 |
26,800 |
44,730 |
Gilad Oren | President/CEO |
Oct 14 '24 |
Buy |
2.59 |
1,000 |
2,590 |
332,645 |
Gilad Oren | President/CEO |
Oct 10 '24 |
Buy |
2.54 |
150 |
381 |
331,645 |
Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 10 '24 |
Buy |
2.61 |
450 |
1,174 |
19,318 |
자본화:
|
볼륨(24시간):